湖南南新制药股份有限公司关于召开2026年第一次临时股东会的通知

Group 1 - The company will hold its first extraordinary general meeting of shareholders in 2026 on February 11, 2026 [1] - The meeting will be conducted both in-person and via the Shanghai Stock Exchange's online voting system [4][20] - Shareholders must register to attend the meeting, either in person or through a proxy [14][17] Group 2 - The major shareholder, Guangzhou Qianyuan Investment Consulting Partnership, held 43,120,000 shares, representing 15.71% of the total share capital before the planned reduction [24] - The reduction plan was announced on September 25, 2025, with a maximum of 8,232,000 shares to be sold, but the plan was not executed by the deadline of January 26, 2026 [25] - The major shareholder did not implement the reduction plan due to personal needs and market conditions [26] Group 3 - The company announced the resignation of independent director Shen Yunqiao due to personal reasons [27] - The board has proposed to elect Luo Zhixiong as the new independent director, who meets all legal and regulatory requirements [28][29] - Luo Zhixiong will also take on roles in various board committees upon approval at the upcoming shareholders' meeting [30]